HALO vs. FOLD: Which Stock Should Value Investors Buy Now?

Core Insights - Halozyme Therapeutics (HALO) is currently viewed as a stronger investment option compared to Amicus Therapeutics (FOLD) for those seeking undervalued stocks [1][3][7] Valuation Metrics - HALO has a forward P/E ratio of 10.63, significantly lower than FOLD's forward P/E of 42.62, indicating HALO may be undervalued [5] - The PEG ratio for HALO is 0.37, while FOLD's PEG ratio is 0.94, suggesting HALO has better expected earnings growth relative to its price [5] - HALO's P/B ratio stands at 11.96 compared to FOLD's 16.14, further supporting HALO's valuation advantage [6] Zacks Rank and Value Grades - HALO holds a Zacks Rank of 2 (Buy), indicating a stronger earnings outlook, while FOLD has a Zacks Rank of 3 (Hold) [3][7] - Based on valuation metrics, HALO has earned a Value grade of A, whereas FOLD has a Value grade of D, highlighting HALO's superior value proposition [6]